Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Seabather's Eruption : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Chickenpox

Contact Dermatitis, Allergic

Eosinophilic Pustular Folliculitis

Folliculitis

Id Reaction (Autoeczematization)

Insect Bites

Jellyfish Stings

Lymphomatoid Papulosis

Papular Urticaria

Parapsoriasis

Psoriasis, Guttate

Urticaria, Acute




Patient Education
Click here for patient education.



Author: Clarence William Brown Jr, MD, Assistant Professor of Dermatology, Director of Mohs Micrographic and Dermatological Surgery, Rush University Medical Center

Clarence William Brown, Jr, is a member of the following medical societies: American Academy of Dermatology and American College of Mohs Micrographic Surgery and Cutaneous Oncology

Editors: Carrie L Kovarik, MD, Assistant Professor, Department of Dermatology and Dermatopathology, University of Pennsylvania School of Medicine; Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA; Jeffrey P Callen, MD, Professor of Medicine, Chief, Division of Dermatology, University of Louisville School of Medicine; Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System

Author and Editor Disclosure

Synonyms and related keywords: sea lice, Linuche unguiculata, L unguiculata, thimble jellyfish larvae

Background

Seabather's eruption was first described in 1949 as a pruritic papular eruption occurring in bathers off the eastern coast of Florida. Seabather's eruption is a highly pruritic, papular eruption that occurs underneath the swimsuit after extended exposure to seawater. Seabather's eruption results from a hypersensitivity to the larval form of the thimble jellyfish, Linuche unguiculata.1 Most cases occur from March to August, but the incidence peaks in May and June.

A related eMedicine article is Cutaneous Manifestations Following Exposures to Marine Life. Additionally, the Medscape CME course Climate Change and Public Health may be of interest.

Pathophysiology

Seabather's eruption is a cutaneous hypersensitivity reaction to the larval form (planulae) of the thimble jellyfish, L unguiculata. The eruption typically occurs underneath the bathing garments, which are believed to trap the jellyfish larvae against the skin. Whether the discharge of venom by the trapped larvae plays an important role in the pathogenesis of the eruption remains uncertain. Factors that promote the discharge of venom by the larvae include wearing of bathing suits for prolonged periods following swimming, exposure to fresh water through showering, and mechanical stimulation.

Frequency

United States

The incidence of seabather's eruption is seasonal; the highest incidence occurs from May through August. This coincides with the warm gulf streams running along the Atlantic coastline of Florida and the corresponding spawn of thimble jellyfish larvae, which results in the high seasonal concentration of Linuche planulae. In 1997, Kumar et al2 reported the occurrence of seabather's eruption in Palm Beach saltwater swimmers in May to be 16%.

International

Seabather's eruption has been reported in Mexico and the Caribbean. The true prevalence of seabather's eruption along international coastlines remains unknown.

Mortality/Morbidity

No deaths have been attributed to exposure to thimble jellyfish larvae.

Race

Seabather's eruption occurs independent of race.

Sex

Seabather's eruption has been noted with equal frequency in both sexes.

Age

No correlation between age and risk for developing seabather's eruption has been noted. The severity of symptoms, particularly the frequency of fever, is greater in children than in adults.



History

The eruption begins a few hours after bathing in the ocean.

  • Pruritus is the most common symptom in patients with seabather's eruption (98%). It typically lasts 1-2 weeks.
  • Fever and malaise are the next most commonly observed symptoms (23%). Fever is observed in 18% of patients. However, 40% of patients younger than 16 years report fever compared with 10% of adults.
  • Systemic symptoms, including fever, nausea, abdominal pain, and diarrhea, are more common in children than in adults.

Physical

On physical examination, patients with seabather's eruption typically display inflammatory papules in a distribution pattern that mimics the bathing suit. Lesions have been noted to occur in the axillae; in men with significant chest hair, they occur on the chest.

  • Relatively rare signs and symptoms of seabather's eruption include the following:
    • Nausea
    • Headache
    • Sore throat
    • Cough
    • Diarrhea
    • Abdominal pain

Causes

Seabather's eruption is caused by exposure to the larval form (planulae) of the thimble jellyfish, L unguiculata.

  • The seasonal variation in the concentrations of thimble jellyfish larvae in endemic areas lead to the increased incidence of seabather's eruption from May through August, with a peak in May and June.
  • Freudenthal and Joseph3 reported the larvae of the sea anemone Edwardsiella lineata as the cause of an outbreak of seabather's eruption on Long Island, New York. This organism also has nematocysts. Various species of Cnidaria larvae in other waters can likely produce similar eruptions.



Chickenpox
Contact Dermatitis, Allergic
Eosinophilic Pustular Folliculitis
Folliculitis
Id Reaction (Autoeczematization)
Insect Bites
Jellyfish Stings
Lymphomatoid Papulosis
Papular Urticaria
Parapsoriasis
Psoriasis, Guttate
Urticaria, Acute

Other Problems to be Considered

Swimmer's itch



Lab Studies

  • Diagnosis of seabather's eruption is made based on the history of exposure and the physical examination. Laboratory studies and skin biopsy are unnecessary.
  • Although only available for research purposes, Wong et al have demonstrated elevated serum levels of immunoglobulin G antibodies specific for L unguiculata.

Procedures

  • A punch biopsy of involved skin may prove useful in narrowing the differential diagnosis when obtaining a reliable history of exposure is difficult.

Histologic Findings

A skin biopsy demonstrates a predominant superficial and deep perivascular and interstitial infiltrate consisting of lymphocytes, eosinophils, and neutrophils. Generally, no epidermal changes are noted, and the dermal-epidermal junction is intact.



Medical Care

Patients with seabather's eruption require only symptomatic or supportive therapy. Children more commonly demonstrate systemic symptoms, including fever, nausea, abdominal pain, and diarrhea. These symptoms may be mistaken for viral gastritis, possibly leading the patient to seek treatment in the emergency department.

  • Use of topical corticosteroids in combination with antihistamines has yielded variable results. Systemic corticosteroids are generally reserved for patients demonstrating severe symptoms.
  • Many anecdotes regarding the effectiveness of alternative remedies made with vinegar, rubbing alcohol, sodium bicarbonate, sugar, urine, olive oil, and meat tenderizer have been reported.

Consultations

A dermatologist can help narrow the differential diagnosis in difficult cases and facilitate a skin biopsy with histologic study.

Activity

Limitations on patients with seabather's eruption are unnecessary unless associated systemic symptoms are severe. However, Kumar et al2 have shown that the risk of developing seabather's eruption in patients exposed to high seasonal concentrations of larvae while swimming in saltwater is significantly reduced if bathers shower with the bathing suit off, regardless of the length of time in the water or the timing of showers.



High-potency topical steroids in combination with oral antihistamines are typically used in treating the cutaneous manifestations of seabather's eruption. Systemic corticosteroids should be reserved for patients with severe rash or pronounced associated systemic symptoms.

Drug Category: Corticosteroids

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli. They are effective in quickly reducing inflammation and pruritus.

Drug NameClobetasol (Temovate)
DescriptionClass I superpotent topical steroid; suppresses mitosis and increases synthesis of proteins that decrease inflammation and cause vasoconstriction. Potent anti-inflammatory properties. Do not use in groin, axilla, or face.
Adult DoseApply to affected areas bid for up to 2 wk; not to exceed 50 g/wk
Pediatric DoseApply sparingly to affected areas bid for 1 wk; limit administration to least amount compatible with effective therapy
ContraindicationsDocumented hypersensitivity; viral or fungal skin infections
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsProlonged exposure to topical corticosteroids can lead to thinning and atrophy of skin as well as suppression of hypothalamic-pituitary-adrenal axis; limit application in adults to no longer than 2 wk; <50 g weekly to avoid above complications

Drug Category: Antihistamines

These agents prevent histamine response in sensory nerve endings and blood vessels. They are more effective in preventing histamine response than in reversing it. They also reduce pruritus.

Drug NameLoratadine (Claritin)
DescriptionSecond-generation antihistamine with very low risk of sedation. Selectively inhibits peripheral histamine H1 receptors.
Adult Dose10 mg PO qd
Pediatric Dose<2 years: Not established
2-6 years: 5 mg/d PO
>6 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsKetoconazole, erythromycin, procarbazine, and alcohol may increase levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsInitiate therapy at lower dose in liver impairment

Drug NameCetirizine (Zyrtec)
DescriptionSecond-generation antihistamine with low risk of sedation. Forms complex with histamine for H1 receptor sites in blood vessels, GI tract, and respiratory tract.
Adult Dose5-10 mg PO qd
Pediatric Dose<2 years: Not established
2-5 years: 2.5 mg PO qd
>5 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsIncreases CNS toxicity of depressants
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsCaution in hepatic or renal dysfunction; doses >10 mg/d may cause drowsiness

Drug NameDesloratadine (Clarinex)
DescriptionLong-acting tricyclic histamine antagonist selective for H1 receptor. Relieves nasal congestion and systemic effects of seasonal allergy. Is a major metabolite of loratadine, which, after ingestion, is metabolized extensively to active metabolite 3-hydroxydesloratadine.
Adult Dose5 mg PO qd
Pediatric Dose<12 years: Not established
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsLimited data exist; erythromycin and ketoconazole increase desloratadine and 3-hydroxydesloratadine plasma concentrations, but no increase in clinically relevant adverse effects, including QTc, was observed
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDecrease dose in hepatic impairment; rarely causes pharyngitis or dry mouth



Further Inpatient Care

  • Patients rarely demonstrate associated systemic symptomatology severe enough to require hospitalization. Even then, treatment is largely supportive and should include systemic corticosteroids.

In/Out Patient Meds

  • Topical corticosteroids in combination with oral antihistamines are used to relieve local symptoms.
  • Systemic corticosteroids should be reserved for patients with a severe cutaneous eruption and pronounced systemic symptoms.

Deterrence/Prevention

  • Showering with the bathing suit off is the only significant protective measure against seabather's eruption. Length of shower time; timing of the shower; bathing suit style; shower water temperature; towel drying upon emerging from the seawater; and application of ointment, creams, or lotions have no preventative effect.

Complications

  • Because of the nature of the allergic hypersensitivity underlying the disease, patients are susceptible to recurrence upon reexposure. Reports have described exaggerated symptomatology in recurrent cases of seabather's eruption, and, for such individuals, avoiding seawater on affected beaches during seasonal peaks is best.

Prognosis

  • Cutaneous eruptions clear in 2 weeks, with or without therapy.

Patient Education



Medical/Legal Pitfalls

  • Failure to make the diagnosis is a pitfall.
    • Thoroughly evaluate children who present with systemic symptoms of fever, malaise, fatigue, and rash to eliminate the diagnosis of bacterial meningitis. The distribution of the rash (that of a bathing suit), along with a history of saltwater exposure during spring and summer months along the eastern coast of Florida, should help to establish the diagnosis.
    • Consultation with a dermatologist proves helpful if an element of doubt exists in the diagnosis.



  1. Segura Puertas L, Burnett JW, Heimer de la Cotera E. The medusa stage of the coronate scyphomedusa Linuche unguiculata ('thimble jellyfish') can cause seabather's eruption. Dermatology. 1999;198(2):171-2. [Medline].
  2. Kumar S, Hlady WG, Malecki JM. Risk factors for seabather's eruption: a prospective cohort study. Public Health Rep. Jan-Feb 1997;112(1):59-62. [Medline].
  3. Freudenthal AR, Joseph PR. Seabather's eruption. N Engl J Med. Aug 19 1993;329(8):542-4. [Medline].
  4. Bernhardt MJ, Mandojana RM. "Seabather's eruption". Clin Dermatol. Jul-Sep 1987;5(3):101-2. [Medline].
  5. Burnett JW, Calton GJ, Burnett HW. Jellyfish envenomation syndromes. J Am Acad Dermatol. Jan 1986;14(1):100-6. [Medline].
  6. Fisher AA. Toxic and allergic cutaneous reactions to jellyfish with special reference to delayed reactions. Cutis. Oct 1987;40(4):303-5. [Medline].
  7. Kettle M. Americans adrift in an ocean of fears. The Guardian Weekly. February 8, 2001:Available at http://www.vuw.ac.nz/~caplabtb/dprk/adrift.html.
  8. Letot B, Kharfi M, Mandojana R, Piérard GE. [Undesirable reactions from contact with marine organisms]. Rev Med Liege. Jun 2000;55(6):531-7. [Medline].
  9. Mandojana RM, Letot B. Historical outlook of aquatic biotoxicology and balneology as related to dermatology. Classification of aquatic dermatoses. Clin Dermatol. Jul-Sep 1987;5(3):1-7. [Medline].
  10. Mandojana RM, Sims JK. Miscellaneous dermatoses associated with the aquatic environment. Clin Dermatol. Jul-Sep 1987;5(3):134-45. [Medline].
  11. Wong DE, Meinking TL, Rosen LB, Taplin D, Hogan DJ, Burnett JW. Seabather's eruption. Clinical, histologic, and immunologic features. J Am Acad Dermatol. Mar 1994;30(3):399-406. [Medline].

Seabather's Eruption excerpt

Article Last Updated: May 22, 2008